Exagen Inc. $XGN Shares Acquired by Sei Investments Co.

Sei Investments Co. boosted its position in Exagen Inc. (NASDAQ:XGN) by 107.0% during the first quarter, Holdings Channel.com reports. The fund owned 244,240 shares of the company’s stock after purchasing an additional 126,235 shares during the quarter. Sei Investments Co.’s holdings in Exagen were worth $733,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in XGN. Bridgeway Capital Management LLC lifted its stake in shares of Exagen by 10.3% in the 2nd quarter. Bridgeway Capital Management LLC now owns 27,800 shares of the company’s stock valued at $194,000 after purchasing an additional 2,600 shares in the last quarter. Truvestments Capital LLC raised its stake in shares of Exagen by 109.5% in the 4th quarter. Truvestments Capital LLC now owns 6,169 shares of the company’s stock valued at $38,000 after acquiring an additional 3,225 shares during the period. State Street Corp raised its stake in shares of Exagen by 6.9% in the 4th quarter. State Street Corp now owns 71,256 shares of the company’s stock valued at $433,000 after acquiring an additional 4,600 shares during the period. Acadian Asset Management LLC acquired a new position in shares of Exagen during the 1st quarter valued at $25,000. Finally, Russell Investments Group Ltd. boosted its position in Exagen by 3.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 229,115 shares of the company’s stock worth $2,518,000 after purchasing an additional 8,499 shares during the period. 75.25% of the stock is currently owned by institutional investors and hedge funds.

Exagen Stock Performance

NASDAQ:XGN opened at $6.58 on Friday. The company has a debt-to-equity ratio of 1.96, a current ratio of 3.18 and a quick ratio of 3.18. The firm has a 50-day moving average of $4.85 and a two-hundred day moving average of $3.94. The stock has a market cap of $159.43 million, a P/E ratio of -8.12 and a beta of 2.05. Exagen Inc. has a 1-year low of $2.59 and a 1-year high of $12.23.

Exagen (NASDAQ:XGN) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.06. Exagen had a negative return on equity of 104.46% and a negative net margin of 26.61%.The company had revenue of $19.94 million during the quarter, compared to the consensus estimate of $17.80 million. On average, research analysts expect that Exagen Inc. will post -0.67 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on XGN shares. BTIG Research increased their price target on Exagen from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Canaccord Genuity Group reduced their price objective on Exagen from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, April 20th. Wall Street Zen raised Exagen from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Exagen in a research note on Friday, August 7th. Finally, Roth Capital began coverage on Exagen in a report on Wednesday, June 24th. They set a “buy” rating and a $8.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $9.62.

About Exagen

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.